新型小分子抑制 Estrogen受体激活功能2 (ER-AF2) 的特性
Jane Foo1, Francesco Gentile1, Shabnam Massah1
1Vancouver Prostate Centre, Department of Urologic Science, University of British Columbia, 2660 Oak Street, Vancouver, BC, V6H 3Z6, Canada.
Breast cancer research : BCR
|November 27, 2024
概括
研究人员开发了一种新型化合物VPC-260724,向雌激素受体 (ER) 激活功能2 (AF2) 部位,以对抗ER阳性乳腺癌的耐药性. 这种新的ER-AF2结合剂显示出抗增殖活性,并可能提供一种补充治疗方法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 雌激素受体 (ER) 阳性乳腺癌经常对当前疗法产生抗性.
- 抵抗机制包括核心调节器过度表达和ER突变,导致构成性活动.
- 针对ER激活函数2 (AF2) 位点提供了一个潜在的策略来克服阻力.
研究的目的:
- 确定针对ER AF2位点的新型抑制剂,以克服治疗耐药性.
- 为ER阳性乳腺癌患者开发一种新的治疗方法,这些患者对现有的治疗方法有抗性.
主要方法:
- 利用人工智能和深度对接来选超过10亿个小分子用于ER AF2结合.
- 采用代的基于细胞和无细胞测试来进行化合物表征和验证.
- 研究了化合物VPC-260724的结合,作用机制和抗增殖作用.
主要成果:
- 确定了290个潜在的ER AF2结合剂,其中VPC-260724作为一种主要化合物,在低微分子范围内抑制ER活性.
- 证实了VPC-260724与ER-AF2部位的直接结合,并破坏了ER-AF2/协同激活剂 (SRC-3) 相互作用.
- 在ER阳性乳腺癌模型中,VPC-260724显示ER基因表达和抗增殖活性降低,包括对他莫西芬耐药的细胞.
结论:
- 开发了VPC-260724,一种新的ER-AF2结合剂,对ER阳性乳腺癌模型具有显著的抗增殖活性.
- VPC-260724是克服对当前ER导向疗法的耐药性的有希望的治疗候选者.
- 与ER-AF2抑制剂的联合治疗可能提供一种新的策略,以改善耐药乳腺癌的治疗结果.
相关概念视频
Transducer Mechanism: Nuclear Receptors
1.3K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.3K
The Two-State Receptor Model
1.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
1.9K
Drug-Receptor Interactions
5.0K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
5.0K
Drug-Receptor Interaction: Agonist
2.4K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.4K
Targets for Drug Action: Overview
6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K


